Loading stock data…
Cybin Inc. (HELP)
$12.39+0.17 (+1.39%)
Market ClosedLast close Sep 8
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cybin D/B/A Helus Pharma in the Healthcare sector is trading at $12.39 with a market capitalization of $365M. Wall Street consensus targets $41.60 (9 analysts), implying a +235.7% move over the next 12 months. The stock is currently near its 52-week high of $14.35, remaining 82.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +235.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$47.86M↓ | -$41.21M↓ | -$28.89M↓ | -$24.62M↑ | -$33.27M |
| Net Income | -$46.99M↓ | -$42.67M↓ | -$33.72M↓ | -$24.61M↑ | -$30.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in pha...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$365.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-63.85%
Volume
Today's trading volume
1.63M
Recent News
Cybin (HELP) Gets A Fresh Look On Trial Progress And CEO Change
Why Cybin Stock Is Back on Investors’ Radar Cybin (HELP) has attracted fresh attention after progress in its psychedelic medicine pipeline, including HLP003 advancing into a Phase 3 trial for major depressive disorder, and the appointment of Michael Halstead as CEO. Cybin’s share price has moved sharply in recent months, with a 1 month share price return of 83.53% and a 90 day share price return of 215.69%. The 1 year total shareholder return of 87.72% contrasts with a weaker 5 year total...
Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions
Cybin’s fair value estimate has moved from US$37.57 to US$41.62 per share, an adjustment of about 11% in the latest analyst model. Recent sector research on psychedelic neuropsychiatry stocks, along with updates around peers’ late stage programs and regulatory tone, is helping shape how analysts frame this higher fair value range for Cybin. Read on to see how these shifting assumptions and new data points can help you track the evolving narrative around the stock. Stay updated as the Fair...
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now
Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003
Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adjunctive treatment for major depressive disorder. Speaking at a Canaccord Genuity event, Halstead, w
Cybin (HELP) Names New CEO, Is The Stock Still Cheap?
Cybin (HELP) is in focus after Helus Pharma appointed Michael Halstead as Chief Executive Officer on 3 August 2026. He brings 25 years of pharmaceutical leadership across product launches, capital markets and major corporate transactions. See our latest analysis for Cybin. The CEO appointment has come alongside sharp share price momentum for Cybin, with a 7 day share price return of 48.47% and a 90 day share price return of 118.64%, although the 5 year total shareholder return is down...